CN113307855A - 拟穴青蟹抗菌多肽Spampcin56-86及其应用 - Google Patents
拟穴青蟹抗菌多肽Spampcin56-86及其应用 Download PDFInfo
- Publication number
- CN113307855A CN113307855A CN202110716770.6A CN202110716770A CN113307855A CN 113307855 A CN113307855 A CN 113307855A CN 202110716770 A CN202110716770 A CN 202110716770A CN 113307855 A CN113307855 A CN 113307855A
- Authority
- CN
- China
- Prior art keywords
- spampcin
- scylla paramamosain
- antibacterial
- antibacterial polypeptide
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 78
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 72
- 241001672730 Scylla paramamosain Species 0.000 title claims abstract description 69
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 69
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 68
- 239000003814 drug Substances 0.000 claims abstract description 18
- 239000003674 animal food additive Substances 0.000 claims abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 241000191967 Staphylococcus aureus Species 0.000 claims description 25
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 14
- 241000607528 Aeromonas hydrophila Species 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 229940124350 antibacterial drug Drugs 0.000 claims description 7
- 241000194031 Enterococcus faecium Species 0.000 claims description 6
- 241000223221 Fusarium oxysporum Species 0.000 claims description 6
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 5
- 241000607522 Aeromonas sobria Species 0.000 claims description 5
- 241000607471 Edwardsiella tarda Species 0.000 claims description 5
- 241000223195 Fusarium graminearum Species 0.000 claims description 5
- 241000589540 Pseudomonas fluorescens Species 0.000 claims description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 241000194032 Enterococcus faecalis Species 0.000 claims description 4
- 241000427940 Fusarium solani Species 0.000 claims description 4
- 241000186781 Listeria Species 0.000 claims description 4
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 4
- 230000002147 killing effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims 4
- 238000009360 aquaculture Methods 0.000 claims 1
- 244000144974 aquaculture Species 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 13
- 230000001954 sterilising effect Effects 0.000 abstract description 9
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 8
- 230000000843 anti-fungal effect Effects 0.000 abstract description 6
- 241000238424 Crustacea Species 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract description 2
- 230000001046 anti-mould Effects 0.000 abstract 1
- 239000002546 antimould Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 description 24
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 5
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 230000035784 germination Effects 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012064 sodium phosphate buffer Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000238102 Scylla Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000002802 antimicrobial activity assay Methods 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 241000589291 Acinetobacter Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000001985 kidney epithelial cell Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
- 102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
- RWDVGVPHEWOZMO-GUBZILKMSA-N Arg-Cys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)C(O)=O RWDVGVPHEWOZMO-GUBZILKMSA-N 0.000 description 1
- ASQKVGRCKOFKIU-KZVJFYERSA-N Arg-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ASQKVGRCKOFKIU-KZVJFYERSA-N 0.000 description 1
- 241000238097 Callinectes sapidus Species 0.000 description 1
- DYBIDOHFRRUMLW-CIUDSAMLSA-N Cys-Leu-Cys Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CS)C(O)=O DYBIDOHFRRUMLW-CIUDSAMLSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000017286 Histone H2A Human genes 0.000 description 1
- 108050005231 Histone H2A Proteins 0.000 description 1
- 241000238553 Litopenaeus vannamei Species 0.000 description 1
- 101500023040 Loxosceles gaucho U1-sicaritoxin-Lg1a Proteins 0.000 description 1
- YZJKNDCEPDDIDA-BZSNNMDCSA-N Phe-His-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CN=CN1 YZJKNDCEPDDIDA-BZSNNMDCSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101150106940 SCY2 gene Proteins 0.000 description 1
- 101710104024 Scygonadin Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102100026166 TFIIA-alpha and beta-like factor Human genes 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108091001629 crustin Proteins 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000009364 mariculture Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000004763 spore germination Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000352 supercritical drying Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
- A01N37/46—N-acyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P3/00—Fungicides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Insects & Arthropods (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
Abstract
本发明公开了一种拟穴青蟹抗菌多肽Spampcin56‑86及其应用,其分子式为C154H256N54O33S3,其氨基酸序列如SEQ ID NO:01所示。本发明的拟穴青蟹抗菌多肽Spampcin56‑86具有较强的抗细菌活性及抗霉菌活性,抗菌效果好,抗菌谱广,杀菌速率快,其来源于甲壳动物,既可以研制成为抗细菌药物和抗霉菌药物,又可以应用于水产饲料添加剂,具有广泛的应用前景。
Description
技术领域
本发明属于海洋分子生物学技术领域,具体涉及一种拟穴青蟹抗菌多肽Spampcin56-86及其应用。
背景技术
据报道,目前我国是全球最大的抗生素生产国和消费国,也是细菌耐药最严重的国家之一,抗生素大量不规范、不合理的使用引发一系列如:细菌耐药性增强、抑制动物免疫、影响人类健康以至破坏生态环境等问题。因此,开发新型高效的抗细菌药物,寻找抗生素有效的替代品成为亟待解决的问题。
抗菌肽(Antibacterialpeptides,AMPs)是一类小分子抗微生物多肽,广泛分布于动植物体内,作为第一道防线以抵御各类病原微生物的感染,是先天性免疫系统中的重要组成部分。主要的抗病机理是作用于病原微生物的细胞膜,使得病原微生物不易对其产生抗性,因而避免耐药性问题的产生且拥有广谱的抗细菌、抗霉菌、抗病毒、抗寄生虫等活性。此外抗菌肽还具备免疫调节剂、信号分子、抗肿瘤等多重角色使其成为极具吸引力的传统抗生素替代品和开发新型抗细菌药物的重要候选材料,并且在转化应用方面也具有相当大的前景。
根据二级结构不同将抗菌肽分为α-抗菌肽、β-抗菌肽和延伸环状抗菌肽;根据携带电荷数的不同将其分为阳离子抗菌肽和阴离子抗菌肽。截至目前,抗微生物肽(CAMPR3)数据库收集到10247条天然肽和合成肽,从海洋动物中也发现并已成功分离了多种具有广谱抗微生物活性的抗菌肽,如Crustins、ALFs、从对虾血淋巴中分离的Penaeidins、源于组蛋白H2A的Sphistin、富含甘氨酸的新型抗菌肽Spgly-AMP以及从青蟹性腺中分离并具有生殖免疫功能的scygonadin和SCY2等。海洋动物处于极端的海洋环境,缺乏获得性免疫,病原感染时主要依靠先天性免疫中的抗菌肽以及免疫效应因子的响应以对抗病原菌。近年来随着海洋生态环境的不断恶化,海水养殖病害频发的问题也日趋明显,因此,加速研发新型的抗菌多肽仍具有重要意义。
发明内容
本发明的目的在于提供一种拟穴青蟹抗菌多肽Spampcin56-86。
本发明的另一目的在于提供上述拟穴青蟹抗菌多肽Spampcin56-86的应用。
本发明的技术方案之一如下:
一种拟穴青蟹抗菌多肽Spampcin56-86,其分子式为C227H373N71O62S1,其氨基酸序列如SEQ ID NO:01所示。
本发明的技术方案之二如下:
上述拟穴青蟹抗菌多肽Spampcin56-86在制备抗细菌药物中的应用,该抗细菌药物对金黄色葡萄球菌及其耐药菌、李斯特菌、粪肠球菌、屎肠球菌、表皮葡萄球菌、铜绿假单胞菌、鲍曼不动杆菌及其耐药菌、温和气单胞菌、嗜水气单胞菌、大肠埃希氏菌及其耐药菌、迟缓爱德华氏菌和荧光假单胞菌具有抑制和杀灭作用。
本发明的技术方案之三如下:
一种抗细菌药物,其有效成分包括上述拟穴青蟹抗菌多肽Spampcin56-86。
在本发明的一个优选实施方案中,其有效成分为上述拟穴青蟹抗菌多肽Spampcin56-86。
本发明的技术方案之四如下:
上述拟穴青蟹抗菌多肽Spampcin56-86在制备防霉菌药物中的应用,该防霉菌药物对尖孢镰孢菌、禾谷镰孢菌和腐皮镰孢菌具有抑制和杀灭作用。
本发明的技术方案之五如下:
一种制备防霉菌药物,其有效成分包括上述拟穴青蟹抗菌多肽Spampcin56-86。
在本发明的一个优选实施方案中,其有效成分为上述拟穴青蟹抗菌多肽Spampcin56-86。
本发明的技术方案之六如下:
上述拟穴青蟹抗菌多肽Spampcin56-86在制备水产饲料添加剂中的应用。
本发明的技术方案之七如下:
一种水产饲料添加剂,其有效成分包括上述拟穴青蟹抗菌多肽Spampcin56-86。
在本发明的一个优选实施方案中,其有效成分为上述拟穴青蟹抗菌多肽Spampcin56-86。
本发明的有益效果是:
1、本发明的拟穴青蟹抗菌多肽Spampcin56-86由31个氨基酸组成,分子式为C154H256N54O33S3,分子量为3488.25道尔顿,其中含有7个带正电的氨基酸残基和0个带负电的氨基酸残基,根据氨基酸残基电荷预测该抗菌肽等电点为11.71,亲水性平均系数为-0.410,是一种带有正电荷的阳离子多肽。
2、本发明的拟穴青蟹抗菌多肽Spampcin56-86对革兰氏阳性菌、革兰氏阴性菌、霉菌均有显著的抗菌效果,此外,Spampcin56-86对正常拟穴青蟹血细胞、正常哺乳动物细胞如小鼠肝实质细胞和人正常肝细胞不具有细胞毒性作用。
3、本发明的拟穴青蟹抗菌多肽Spampcin56-86具有较强的抗细菌活性及抗霉菌活性,抗菌效果好,抗菌谱广,杀菌速率快,其来源于甲壳动物,既可以研制成为抗细菌药物和抗霉菌药物,又可以应用于水产饲料添加剂,具有广泛的应用前景。
附图说明
图1为本发明实施例3中拟穴青蟹抗菌多肽Spampcin56-86对金黄色葡萄球菌、铜绿假单胞菌、嗜水气单胞菌、大肠埃希氏菌的杀菌动力学图;其中,横坐标为时间(min),纵坐标为杀菌指数(%)。
图2为本发明实施例4中拟穴青蟹抗菌多肽Spampcin56-86对金黄色葡萄球菌、铜绿假单胞菌抗菌热稳定性图;其中,横坐标为时间(h),纵坐标为OD600值。
图3为本发明实施例5中拟穴青蟹抗菌多肽Spampcin56-86抑制禾谷镰孢菌孢子萌发实验图;其中,拟穴青蟹抗菌多肽Spampcin56-86浓度为:A:0μM,B:6μM,C:12μM;
图4为本发明实施例5中拟穴青蟹抗菌多肽Spampcin56-86抑制尖孢镰孢菌孢子萌发实验图;其中,拟穴青蟹抗菌多肽Spampcin56-86浓度为:A:0μM,B:6μM,C:12μM;
图5为本发明实施例6中拟穴青蟹抗菌多肽Spampcin56-86与金黄色葡萄球菌作用后的扫描电镜观察图;其中,A:金黄色葡萄球菌,B:金黄色葡萄球菌+12μM Spampcin56-86。
图6为本发明实施例6中拟穴青蟹抗菌多肽Spampcin56-86与铜绿假单胞菌作用后的扫描电镜观察图;其中,A:铜绿假单胞菌,B:铜绿假单胞菌+12μM Spampcin56-86。
图7为MTS-PMS法检测拟穴青蟹抗菌多肽Spampcin56-86细胞毒性实验图;其中,横坐标为Spampcin56-86蛋白浓度(μM),纵坐标为细胞增殖率(%)。
具体实施方式
以下通过具体实施方式结合附图对本发明的技术方案进行进一步的说明和描述。
实施例1拟穴青蟹抗菌多肽Spampcin56-86的制备
所述拟穴青蟹抗菌多肽Spampcin56-86的氨基酸序列为:
Arg-Arg-Ala-Ala-His-Gly-Leu-Leu-Pro-Arg-Leu-Arg-Ala-Pro-Pro-Pro-Phe-His-Lys-Arg-Cys-Val-Cys-Leu-Cys-Arg-Thr-Ala-Pro-Pro-Pro(SEQ ID NO:01)
采用现有的固相化学合成的方法即可得到纯度达95%以上拟穴青蟹抗菌多肽Spampcin56-86。本实施例中的拟穴青蟹抗菌多肽Spampcin56-86委托金斯瑞(江苏)有限公司以固相合成方法合成获得并提供多肽分子量、HPLC等检测信息。拟穴青蟹抗菌多肽Spampcin56-86理化参数如表1所示:
表1拟穴青蟹抗菌多肽Spampcin56-86理化参数
由表1可知Spampcin56-86分子量小、稳定性较好,是一种带有正电荷的阳离子多肽。
实施例2拟穴青蟹抗菌多肽Spampcin56-86最小抑菌浓度(MIC)和最小杀菌浓度(MBC)的测定
本实施例中所涉及到的菌株有:金黄色葡萄球菌(Staphylococcusaureus)、表皮葡萄球菌(Staphylococcusepidermidis)、屎肠球菌(Enterococcusfaecium)、粪肠球菌(Enterococcusfaecalis)、李斯特菌(Listeriamonocytogenes)、大肠埃希氏菌(Escherichiacoli)、铜绿假单胞菌(Pseudomonashydrophila)、嗜水气单胞菌(Aeromonashydrophila)、温和气单胞菌(Aeromonassobria)、迟缓爱德华氏菌(Edwardsiellatarda)、荧光假单胞菌(Pseudomonasfluorescens)、鲍曼不动杆菌(Acinetobacterbaumannii)、耐药金黄色葡萄球菌(Staphylococcus aureus)、耐药鲍曼不动杆菌(Acinetobacterbaumannii)、耐药大肠埃希氏菌(Escherichiacoli)、尖孢镰孢菌(Fusariumoxysporum)、禾谷镰孢菌(Fusarium graminearum)、腐皮镰孢菌(Fusariumsolani)。其中温和气单胞菌、迟缓爱德华氏菌来源福建省水产研究所赠送,临床分离菌株耐药金黄色葡萄球菌、耐药鲍曼不动杆菌及耐药大肠埃希氏菌来源福建医科大学附属第二医院检验科,其余菌株均购自中国科学院微生物研究所菌种保藏中心,由本实验室保种贮藏。
具体方法如下:
(1)将保种的金黄色葡萄球菌、表皮葡萄球菌、李斯特菌、屎肠球菌、粪肠球菌、大肠埃希氏菌、铜绿假单胞菌、嗜水气单胞菌、温和气单胞菌、迟缓爱德华氏菌、荧光假单胞菌、鲍曼不动杆菌、耐药金黄色葡萄球菌、耐药鲍曼不动杆和耐药大肠埃希氏菌涂布于营养肉汤平板上,在各适宜温度倒置培养18-24h;尖孢镰孢菌、禾谷镰孢菌、腐皮镰孢菌涂布于马铃薯葡萄糖平板上,于28℃倒置培养1-7d。
(2)从各平板上挑取菌落接种于相应的培养基斜面上,细菌继续培养18-24h,用10mM磷酸钠缓冲液(pH=7.4)将细菌从斜面上冲下,调整菌悬液浓度。用MH液体培养基和磷酸钠缓冲液混合液稀释细菌,使得菌体的最终浓度为3.3×104CFU/mL。用10mM磷酸钠缓冲液(pH=7.4)将霉菌孢子从斜面上冲下,用马铃薯葡萄糖液体培养基和磷酸钠缓冲液混合液稀释孢子,利用血球计数板在光学显微镜下对孢子计数,调整孢子浓度,使得霉菌孢子最终浓度为5×104个/mL。
(3)将已合成的拟穴青蟹抗菌多肽Spampcin56-86粉末分别用灭菌MiliiQ水溶解,经过0.22μM滤膜过滤后,倍比稀释蛋白浓度至3μM、6μM、12μM、24μM、48μM、96μM,置于冰上备用。
(4)在96孔细胞培养板上,每种待测菌设置空白对照组、阴性对照组和待测实验组,每组设置三个平行:
a空白对照组:50μL待测蛋白样品和50μL培养基
b阴性对照组:50μL无菌MilliQ水和50μL菌悬液
c待测实验组:50μL待测蛋白样品和50μL菌悬液
(5)将96孔细胞培养板置于28℃培养箱中,培养1-2d,观察待测实验组中MIC结果;将待测实验组吹打混匀后,吸取适量的菌液滴于相应固体培养基平板上,于适宜温度倒置培养1-2d,观察MBC结果。
拟穴青蟹抗菌多肽Spampcin56-86的MIC、MBC观察结果如表2所示
表2拟穴青蟹抗菌多肽Spampcin56-86的抗细菌和抗霉菌活性
注:MIC:最小抑菌浓度(μM),用a-b表示。a:肉眼可见菌体生长的最高蛋白浓度;b:肉眼未见菌体生长的最低蛋白浓度。
MBC:最小杀菌浓度(μM),用a-b表示。a:平板可见菌落生长的最高蛋白浓度;b:平板未见菌落生长的最低蛋白浓度。
实施例3拟穴青蟹抗菌多肽Spampcin56-86杀菌动力学曲线
选取金黄色葡萄球菌、铜绿假单胞菌、嗜水气单胞菌和大肠埃希氏菌作为待测菌,对拟穴青蟹抗菌多肽Spampcin56-86的杀菌动力学进行测定。
具体方法如实施例2中所述的抗菌活性测定类似。调整拟穴青蟹抗菌多肽Spampcin56-86终浓度至1倍MBC(金黄色葡萄球菌:6μM;铜绿假单胞菌:6μM;嗜水气单胞菌:12μM;大肠埃希氏菌:6μM;)。在共孵后2min、8min、10min、20min、25min、30min,将96孔细胞培养板取空白对照组、阴性对照组、待测实验组混匀,吸取6μL金黄色葡萄球菌菌悬液稀释至600μLDPBS中,混匀后吸取20μL涂布至营养肉汤平板上,37℃倒置培养1-2d,记录金黄色葡萄球菌单克隆数量,计算杀菌指数。在共孵后2min、4min、5min、10min、15min、20min、30min,将96孔细胞培养板取空白对照组、阴性对照组、待测实验组混匀,吸取6μL铜绿假单胞菌菌悬液稀释至600μLDPBS中,吸取40μL铜绿假单胞菌菌悬液涂布至营养肉汤平板上,37℃倒置培养1-2d,记录铜绿假单胞菌单克隆数量,计算杀菌指数。在共孵后10min、30min、60min、120min、150min,将96孔细胞培养板取空白对照组、阴性对照组、待测实验组混匀,吸取6μL嗜水气单胞菌菌悬液稀释至720μLDPBS中,吸取20μL嗜水气单胞菌菌悬液涂布至营养肉汤平板上,28℃倒置培养1-2d,记录嗜水气单胞菌单克隆数量,计算杀菌指数。在共孵后10min、15min、20min、30min、60min,将96孔细胞培养板取空白对照组、阴性对照组、待测实验组混匀,吸取6μL大肠埃希氏菌菌悬液稀释至720μLDPBS中,吸取20μL大肠埃希氏菌菌悬液涂布至营养肉汤平板上,37℃倒置培养1-2d,记录大肠埃希氏菌单克隆数量,计算杀菌指数。杀菌指数是指经过一定时间共孵后,待测实验组的克隆数与阴性对照组克隆数的比值,用百分比表示,结果如图1所示。
实施例4拟穴青蟹抗菌多肽Spampcin56-86抗菌活性热稳定性
选取金黄色葡萄球菌和铜绿假单胞菌作为待测菌,对拟穴青蟹抗菌肽Spampcin56-86的抗菌活性热稳定性进行测定。
具体方法如实施例2中所述的抗菌活性测定类似。调整拟穴青蟹抗菌肽Spampcin56-86终浓度至1倍MBC(金黄色葡萄球菌:6μM,铜绿假单胞菌:6μM),分别在100℃沸水中水浴10min、20min、30min后置于冰上备用。将Spampcin56-86与待测菌共同孵育,在0h、12h、24h、36h、48h时用酶标仪测定OD600的值,结果如图2所示。
实施例5拟穴青蟹抗菌多肽Spampcin56-86作用后霉菌孢子萌发显微镜观察
选取尖孢镰孢、禾谷镰孢作为待测菌,观察拟穴青蟹抗菌肽Spampcin56-86对霉菌孢子萌发的影响。
具体方法如实施例2中所述的抗菌活性测定类似。调整拟穴青蟹抗菌肽Spampcin56-86蛋白浓度为6μM、12μM,置于冰上备用;调整各霉菌孢子最终浓度为5×104个/mL。将等体积各浓度Spampcin56-86与各霉菌孢子于96孔细胞培养板混匀,置于28℃培养箱中,静置培养24h,在光学显微镜下观察霉菌孢子萌发情况,结果如图3和图4所示。
实施例6拟穴青蟹抗菌多肽Spampcin56-86与细菌作用后的扫描电镜观察
选取金黄色葡萄球菌、铜绿假单胞菌作为待测菌株,扫描电镜样品的制备按以下步骤进行:
(1)如实施例2所述制备金黄色葡萄球菌、铜绿假单胞菌菌悬液(OD600=0.4)冰上放置备用。
(2)用灭菌纯水溶解合成拟穴青蟹抗菌多肽Spampcin56-86,并调整蛋白浓度为12μM,冰上放置备用。
(3)菌悬液和蛋白等体积混合后在适宜温度孵育适宜时间。其中金黄色葡萄球菌菌悬液与12μM拟穴青蟹抗菌多肽Spampcin56-86于37℃孵育10min;铜绿假单胞菌菌悬液与12μM拟穴青蟹抗菌多肽Spampcin56-86于37℃孵育30min。
(4)加入等体积戊二醛固定液,4℃固定2h后,1000g离心10min。
(5)去尽上清,PBS清洗一次,1000g离心10min。
(6)去除大部分上清,留约10μL液体,将剩余悬液滴在玻片上,4℃静置过夜。
(7)PBS清洗一次。
(8)30%-50%-70%-80%-90%-95%-100%-100%(v/v)乙醇逐级脱水,每级脱水15min。
(9)临界点干燥法干燥样品。
(10)喷金后用扫描电子显微镜观察及拍照,结果如图5和图6所示。
实施例7拟穴青蟹抗菌多肽Spampcin56-86细胞毒性测定
选取人肾上皮细胞(HEK-293T)和拟穴青蟹正常血细胞,对拟穴青蟹抗菌肽Spampcin56-86细胞毒性进行测定。具体如下:
(1)收集生长状态良好的拟穴青蟹血细胞、人肾上皮细胞,调整细胞浓度为1×105个/mL,将细胞均匀吹散,在96孔细胞培养板中每孔加入100μL细胞悬液,置于适宜温度培养箱培养至80%以上细胞贴壁。
(2)小心吸出培养基,加入含有不同浓度(0μM、3μM、6μM、12μM、24μM、48μM)拟穴青蟹抗菌多肽Spampcin56-86的培养基,置于适宜温度培养箱培养24h。
(3)加入20μLMTS-PMS溶液后避光孵育2h后,使用酶标仪测得OD492值,评价拟穴青蟹抗菌多肽Spampcin56-86的细胞毒性,结果如图7所示。
以上所述,仅为本发明的较佳实施例而已,故不能依此限定本发明实施的范围,即依本发明专利范围及说明书内容所作的等效变化与修饰,皆应仍属本发明涵盖的范围内。
序列表
<110> 厦门大学
<120> 拟穴青蟹抗菌多肽Spampcin56-86及其应用
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 30
<212> PRT
<213> 拟穴青蟹(Scylla paramamosain)
<400> 1
Arg Arg Ala Ala His Gly Leu Leu Pro Arg Leu Arg Ala Pro Pro Pro
1 5 10 15
Phe His Lys Arg Cys Val Cys Leu Cys Arg Thr Ala Pro Pro
20 25 30
Claims (10)
1.拟穴青蟹抗菌多肽Spampcin56-86,其特征在于:其分子式为C154H256N54O33S3,其氨基酸序列如SEQ ID NO:01所示。
2.权利要求1所述的拟穴青蟹抗菌多肽Spampcin56-86在制备抗细菌药物中的应用,其特征在于:该抗细菌药物对金黄色葡萄球菌及其耐药菌、李斯特菌、粪肠球菌、屎肠球菌、表皮葡萄球菌、铜绿假单胞菌、鲍曼不动杆菌及其耐药菌、温和气单胞菌、嗜水气单胞菌、大肠埃希氏菌及其耐药菌、迟缓爱德华氏菌和荧光假单胞菌具有抑制和杀灭作用。
3.一种抗细菌药物,其特征在于:其有效成分包括如权利要求1所述的拟穴青蟹抗菌多肽Spampcin56-86。
4.如权利要求3所述的抗细菌药物,其特征在于:其有效成分为如权利要求1所述的拟穴青蟹抗菌多肽Spampcin56-86。
5.权利要求1所述的拟穴青蟹抗菌多肽Spampcin56-86在制备防霉菌药物中的应用,其特征在于:该防霉菌药物对尖孢镰孢菌、禾谷镰孢菌和腐皮镰孢菌具有抑制和杀灭作用。
6.一种防霉菌药物,其特征在于:其有效成分包括如权利要求1所述的拟穴青蟹抗菌多肽Spampcin56-86。
7.如权利要求6所述的防霉菌药物,其特征在于:其有效成分为如权利要求1所述的拟穴青蟹抗菌多肽Spampcin56-86。
8.权利要求1所述的拟穴青蟹抗菌多肽Spampcin56-86在制备水产饲料添加剂中的应用。
9.一种水产饲料添加剂,其特征在于:其有效成分包括如权利要求1所述的拟穴青蟹抗菌多肽Spampcin56-86。
10.如权利要求9所述的水产饲料添加剂,其特征在于:其有效成分为如权利要求1所述的拟穴青蟹抗菌多肽Spampcin56-86。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110716770.6A CN113307855B (zh) | 2021-06-25 | 2021-06-25 | 拟穴青蟹抗菌多肽Spampcin56-86及其应用 |
PCT/CN2022/100406 WO2022268115A1 (zh) | 2021-06-25 | 2022-06-22 | 拟穴青蟹抗菌多肽Spampcin 56-86及其应用 |
US18/454,855 US12102086B2 (en) | 2021-06-25 | 2023-08-24 | Antimicrobial peptide Spampcin56-86 from Scylla paramamosain and applications thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110716770.6A CN113307855B (zh) | 2021-06-25 | 2021-06-25 | 拟穴青蟹抗菌多肽Spampcin56-86及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113307855A true CN113307855A (zh) | 2021-08-27 |
CN113307855B CN113307855B (zh) | 2023-08-01 |
Family
ID=77380546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110716770.6A Active CN113307855B (zh) | 2021-06-25 | 2021-06-25 | 拟穴青蟹抗菌多肽Spampcin56-86及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US12102086B2 (zh) |
CN (1) | CN113307855B (zh) |
WO (1) | WO2022268115A1 (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113999296A (zh) * | 2021-11-04 | 2022-02-01 | 厦门大学 | 一种拟穴青蟹新型抗菌多肽Spgillcin177-189及其应用 |
CN114014910A (zh) * | 2021-11-18 | 2022-02-08 | 厦门大学 | 一种拟穴青蟹抗真菌多肽Spamptin72-91及其应用 |
CN114773436A (zh) * | 2022-04-27 | 2022-07-22 | 厦门大学 | 一种拟穴青蟹抗菌多肽SpRR20及其应用 |
CN114957429A (zh) * | 2022-06-09 | 2022-08-30 | 厦门大学 | 一种青蟹广谱抗菌多肽Scyrephemin60-81及其应用 |
CN114957430A (zh) * | 2022-06-09 | 2022-08-30 | 厦门大学 | 一种拟穴青蟹抗菌多肽Sparepcin173-194及其应用 |
CN115246876A (zh) * | 2022-06-09 | 2022-10-28 | 厦门大学 | 一种拟穴青蟹抗菌多肽Scyrepsin34-55及其应用 |
WO2022268115A1 (zh) * | 2021-06-25 | 2022-12-29 | 厦门大学 | 拟穴青蟹抗菌多肽Spampcin 56-86及其应用 |
CN116143883A (zh) * | 2022-10-19 | 2023-05-23 | 厦门大学 | 一种广谱抗微生物肽Scymicrosin7-26及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6614348A (zh) * | 1965-10-13 | 1967-04-14 | ||
CN102167736A (zh) * | 2011-05-17 | 2011-08-31 | 厦门大学 | 一种拟穴青蟹抗菌肽Sphistin及其应用 |
US10208088B1 (en) * | 2015-06-15 | 2019-02-19 | Sichuan Synlight Biotech Ltd. | Low molecular polypeptide ZY4 and applications thereof |
CN111051335A (zh) * | 2018-06-20 | 2020-04-21 | 厦门大学 | 一种拟穴青蟹抗菌肽Sparamosin及其应用 |
KR102146779B1 (ko) * | 2020-03-20 | 2020-08-24 | 유피씨(주) | 항균소취조성물과 이의 제조방법 및 이를 이용한 통기성 폴리에틸렌 합지원단으로 제조한 방호복 |
CN112955460A (zh) * | 2019-12-31 | 2021-06-11 | 厦门大学 | 一种拟穴青蟹抗菌肽Scyreprocin新功能及其应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018798A1 (en) * | 1998-09-25 | 2000-04-06 | Xoma Technology Ltd. | Antifungal and antibacterial peptide |
US10059752B2 (en) * | 2013-10-14 | 2018-08-28 | University Of Houston System | Esculentin 1a derivatives and uses thereof |
CN103789317A (zh) * | 2014-01-08 | 2014-05-14 | 广西壮族自治区海洋研究所 | 拟穴青蟹抗菌肽hyastatin基因克隆及编码蛋白重组和用途 |
CN105274134A (zh) * | 2015-11-25 | 2016-01-27 | 厦门大学 | 拟穴青蟹抗菌肽scy2的制备方法与应用 |
CN110028568B (zh) * | 2019-03-11 | 2021-06-01 | 厦门大学 | 一种拟穴青蟹抗菌多肽Sp-NPFin及其应用 |
CN112159460B (zh) * | 2020-09-29 | 2021-12-17 | 厦门大学 | 一种拟穴青蟹抗菌肽Spamprin4-23及其应用 |
CN112724221B (zh) * | 2021-01-26 | 2022-03-15 | 厦门大学 | 拟穴青蟹抗菌肽Spamplin58-82及其应用 |
CN113307855B (zh) * | 2021-06-25 | 2023-08-01 | 厦门大学 | 拟穴青蟹抗菌多肽Spampcin56-86及其应用 |
-
2021
- 2021-06-25 CN CN202110716770.6A patent/CN113307855B/zh active Active
-
2022
- 2022-06-22 WO PCT/CN2022/100406 patent/WO2022268115A1/zh active Application Filing
-
2023
- 2023-08-24 US US18/454,855 patent/US12102086B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6614348A (zh) * | 1965-10-13 | 1967-04-14 | ||
CN102167736A (zh) * | 2011-05-17 | 2011-08-31 | 厦门大学 | 一种拟穴青蟹抗菌肽Sphistin及其应用 |
US10208088B1 (en) * | 2015-06-15 | 2019-02-19 | Sichuan Synlight Biotech Ltd. | Low molecular polypeptide ZY4 and applications thereof |
CN111051335A (zh) * | 2018-06-20 | 2020-04-21 | 厦门大学 | 一种拟穴青蟹抗菌肽Sparamosin及其应用 |
CN112955460A (zh) * | 2019-12-31 | 2021-06-11 | 厦门大学 | 一种拟穴青蟹抗菌肽Scyreprocin新功能及其应用 |
KR102146779B1 (ko) * | 2020-03-20 | 2020-08-24 | 유피씨(주) | 항균소취조성물과 이의 제조방법 및 이를 이용한 통기성 폴리에틸렌 합지원단으로 제조한 방호복 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12102086B2 (en) | 2021-06-25 | 2024-10-01 | Xiamen University | Antimicrobial peptide Spampcin56-86 from Scylla paramamosain and applications thereof |
WO2022268115A1 (zh) * | 2021-06-25 | 2022-12-29 | 厦门大学 | 拟穴青蟹抗菌多肽Spampcin 56-86及其应用 |
CN113999296B (zh) * | 2021-11-04 | 2022-11-01 | 厦门大学 | 一种拟穴青蟹新型抗菌多肽Spgillcin177-189及其应用 |
CN113999296A (zh) * | 2021-11-04 | 2022-02-01 | 厦门大学 | 一种拟穴青蟹新型抗菌多肽Spgillcin177-189及其应用 |
CN114014910A (zh) * | 2021-11-18 | 2022-02-08 | 厦门大学 | 一种拟穴青蟹抗真菌多肽Spamptin72-91及其应用 |
CN114773436A (zh) * | 2022-04-27 | 2022-07-22 | 厦门大学 | 一种拟穴青蟹抗菌多肽SpRR20及其应用 |
CN114957429A (zh) * | 2022-06-09 | 2022-08-30 | 厦门大学 | 一种青蟹广谱抗菌多肽Scyrephemin60-81及其应用 |
CN115246876A (zh) * | 2022-06-09 | 2022-10-28 | 厦门大学 | 一种拟穴青蟹抗菌多肽Scyrepsin34-55及其应用 |
CN114957429B (zh) * | 2022-06-09 | 2023-11-21 | 厦门大学 | 一种青蟹广谱抗菌多肽Scyrephemin60-81及其应用 |
CN114957430B (zh) * | 2022-06-09 | 2023-12-12 | 厦门大学 | 一种拟穴青蟹抗菌多肽Sparepcin173-194及其应用 |
CN114957430A (zh) * | 2022-06-09 | 2022-08-30 | 厦门大学 | 一种拟穴青蟹抗菌多肽Sparepcin173-194及其应用 |
CN116143883A (zh) * | 2022-10-19 | 2023-05-23 | 厦门大学 | 一种广谱抗微生物肽Scymicrosin7-26及其应用 |
CN116143883B (zh) * | 2022-10-19 | 2024-09-06 | 厦门大学 | 一种广谱抗微生物肽Scymicrosin7-26及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20230404076A1 (en) | 2023-12-21 |
CN113307855B (zh) | 2023-08-01 |
US12102086B2 (en) | 2024-10-01 |
WO2022268115A1 (zh) | 2022-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113307855B (zh) | 拟穴青蟹抗菌多肽Spampcin56-86及其应用 | |
CN112159460B (zh) | 一种拟穴青蟹抗菌肽Spamprin4-23及其应用 | |
CN110028568B (zh) | 一种拟穴青蟹抗菌多肽Sp-NPFin及其应用 | |
CN114014923B (zh) | 拟穴青蟹抗菌多肽Sp-LECin及其应用 | |
CN112724221B (zh) | 拟穴青蟹抗菌肽Spamplin58-82及其应用 | |
CN112707961B (zh) | 一种贝类抗菌肽p-amp153及其应用 | |
CN113121666B (zh) | 抗菌肽Scybaumancin105-127及其应用 | |
CN110776560B (zh) | 一种黑鲷抗菌肽AS-hepc3(48-56)及其应用 | |
CN114716512A (zh) | 一种青蟹广谱抗菌肽Scyampcin44-63及其应用 | |
CN110498848B (zh) | 一种蜂毒肽变体及其应用 | |
CN113999296B (zh) | 一种拟穴青蟹新型抗菌多肽Spgillcin177-189及其应用 | |
CN113214355B (zh) | 一种专杀真菌的抗菌肽gl4w及其制备方法和应用 | |
CN106632606B (zh) | 抗菌脂肽bacaucin衍生物及其在抑制细菌感染中的应用 | |
CN110551191B (zh) | 一种低溶血活性的蜂毒肽及其应用 | |
CN114773436B (zh) | 一种拟穴青蟹抗菌多肽SpRR20及其应用 | |
CN114957429B (zh) | 一种青蟹广谱抗菌多肽Scyrephemin60-81及其应用 | |
CN113045629A (zh) | 抗菌肽BIMix及其应用 | |
CN107827988B (zh) | 嵌合穿膜抗菌肽t11n2及其应用 | |
CN114957430B (zh) | 一种拟穴青蟹抗菌多肽Sparepcin173-194及其应用 | |
CN115246876B (zh) | 一种拟穴青蟹抗菌多肽Scyrepsin34-55及其应用 | |
CN115028692B (zh) | 枯草芽孢杆菌抗菌肽BsR1及其应用 | |
CN116925204A (zh) | 一种拟穴青蟹抗菌多肽Spgilstin10-33及其应用 | |
CN114014910B (zh) | 一种拟穴青蟹抗真菌多肽Spamptin72-91及其应用 | |
CN114349825B (zh) | 一种蝎毒衍生肽及其在制备抗菌或抗炎药物中的应用 | |
CN117264040A (zh) | 一种拟穴青蟹新型抗菌肽Scyreptin及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |